Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
HITK's Cash to Debt is ranked higher than
98% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. HITK: No Debt )
HITK' s 10-Year Cash to Debt Range
Min: 0.03   Max: 13069
Current: No Debt

0.03
13069
Equity to Asset 0.90
HITK's Equity to Asset is ranked higher than
95% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. HITK: 0.90 )
HITK' s 10-Year Equity to Asset Range
Min: 0.58   Max: 0.91
Current: 0.9

0.58
0.91
Interest Coverage 69.19
HITK's Interest Coverage is ranked higher than
65% of the 454 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.71 vs. HITK: 69.19 )
HITK' s 10-Year Interest Coverage Range
Min: 4.67   Max: 1548.03
Current: 69.19

4.67
1548.03
F-Score: 5
Z-Score: 14.42
M-Score: -2.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.11
HITK's Operating margin (%) is ranked higher than
85% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. HITK: 16.11 )
HITK' s 10-Year Operating margin (%) Range
Min: -11.8   Max: 30.98
Current: 16.11

-11.8
30.98
Net-margin (%) 6.99
HITK's Net-margin (%) is ranked higher than
73% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. HITK: 6.99 )
HITK' s 10-Year Net-margin (%) Range
Min: -8.22   Max: 21.72
Current: 6.99

-8.22
21.72
ROE (%) 6.62
HITK's ROE (%) is ranked higher than
72% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. HITK: 6.62 )
HITK' s 10-Year ROE (%) Range
Min: -6.78   Max: 23.09
Current: 6.62

-6.78
23.09
ROA (%) 5.51
HITK's ROA (%) is ranked higher than
79% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. HITK: 5.51 )
HITK' s 10-Year ROA (%) Range
Min: -6   Max: 20.71
Current: 5.51

-6
20.71
ROC (Joel Greenblatt) (%) 34.80
HITK's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. HITK: 34.80 )
HITK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14.3   Max: 61.77
Current: 34.8

-14.3
61.77
Revenue Growth (%) 9.90
HITK's Revenue Growth (%) is ranked higher than
76% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HITK: 9.90 )
HITK' s 10-Year Revenue Growth (%) Range
Min: 1.6   Max: 39
Current: 9.9

1.6
39
EBITDA Growth (%) -14.50
HITK's EBITDA Growth (%) is ranked higher than
56% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HITK: -14.50 )
HITK' s 10-Year EBITDA Growth (%) Range
Min: -14.5   Max: 52.6
Current: -14.5

-14.5
52.6
EPS Growth (%) -22.30
HITK's EPS Growth (%) is ranked higher than
58% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HITK: -22.30 )
HITK' s 10-Year EPS Growth (%) Range
Min: -22.3   Max: 62.3
Current: -22.3

-22.3
62.3
» HITK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HITK Guru Trades in Q3 2013

Mario Gabelli 218,667 sh (New)
Jim Simons 89,500 sh (+255.86%)
Paul Tudor Jones Sold Out
Chuck Royce 700 sh (-99.96%)
» More
Q4 2013

HITK Guru Trades in Q4 2013

Paul Tudor Jones 10,172 sh (New)
Jim Simons 121,000 sh (+35.2%)
Mario Gabelli 219,667 sh (+0.46%)
Chuck Royce 700 sh (unchged)
» More
Q1 2014

HITK Guru Trades in Q1 2014

Jim Simons 280,072 sh (+131.46%)
Mario Gabelli 276,167 sh (+25.72%)
Paul Tudor Jones 11,063 sh (+8.76%)
Chuck Royce 700 sh (unchged)
» More
Q2 2014

HITK Guru Trades in Q2 2014

Mario Gabelli Sold Out
Chuck Royce Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HITK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-06-30 Sold Out 0.07%$43.31 - $43.5 $ 43.490%0
Mario Gabelli 2014-03-31 Add 25.72%0.01%$43.17 - $43.515 $ 43.490%276167
Mario Gabelli 2013-09-30 New Buy0.06%$33.02 - $43.19 $ 43.4914%218667
Joel Greenblatt 2012-09-30 Sold Out 0.12%$29.2 - $36.54 $ 43.4932%0
Joel Greenblatt 2011-09-30 Add 39.49%0.06%$24.61 - $34.71 $ 43.4947%38446
Joel Greenblatt 2011-06-30 New Buy0.11%$20.45 - $28.74 $ 43.4968%27561
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Hi-Tech Pharmacal Co., Inc.

Chuck Royce Reductions – Lessons on Hold’em or Fold’em
If investors are to learn by example of the billionaire gurus, Chuck Royce’s trades offer a valuable lesson in “when to hold’em and when to fold’em." As the king of small caps, Royce has a strategy that’s definitely working, with an average return of 19.78% over 12 months. His 12-month average is higher than 64 other billionaire investors. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 65.90
HITK's P/E(ttm) is ranked higher than
65% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. HITK: 65.90 )
HITK' s 10-Year P/E(ttm) Range
Min: 6.41   Max: 91.33
Current: 65.9

6.41
91.33
P/B 2.24
HITK's P/B is ranked higher than
74% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. HITK: 2.24 )
HITK' s 10-Year P/B Range
Min: 0.6   Max: 4.83
Current: 2.24

0.6
4.83
P/S 2.67
HITK's P/S is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. HITK: 2.67 )
HITK' s 10-Year P/S Range
Min: 0.59   Max: 5.38
Current: 2.67

0.59
5.38
EV-to-EBIT 14.05
HITK's EV-to-EBIT is ranked higher than
90% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. HITK: 14.05 )
HITK' s 10-Year EV-to-EBIT Range
Min: 3.4   Max: 418.2
Current: 14.05

3.4
418.2
PEG 5.15
HITK's PEG is ranked higher than
84% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. HITK: 5.15 )
HITK' s 10-Year PEG Range
Min: 0.52   Max: 11.99
Current: 5.15

0.52
11.99
Shiller P/E 20.07
HITK's Shiller P/E is ranked higher than
87% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. HITK: 20.07 )
HITK' s 10-Year Shiller P/E Range
Min: 11.8   Max: 66.79
Current: 20.07

11.8
66.79
Current Ratio 8.11
HITK's Current Ratio is ranked higher than
92% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. HITK: 8.11 )
HITK' s 10-Year Current Ratio Range
Min: 1.68   Max: 8.74
Current: 8.11

1.68
8.74
Quick Ratio 6.41
HITK's Quick Ratio is ranked higher than
92% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. HITK: 6.41 )
HITK' s 10-Year Quick Ratio Range
Min: 1.05   Max: 7.75
Current: 6.41

1.05
7.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.82
HITK's Price/Net Cash is ranked higher than
93% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. HITK: 10.82 )
HITK' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 66.63
Current: 10.82

3.9
66.63
Price/Net Current Asset Value 4.56
HITK's Price/Net Current Asset Value is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. HITK: 4.56 )
HITK' s 10-Year Price/Net Current Asset Value Range
Min: 2.03   Max: 75
Current: 4.56

2.03
75
Price/Tangible Book 2.60
HITK's Price/Tangible Book is ranked higher than
81% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. HITK: 2.60 )
HITK' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 7
Current: 2.6

0.84
7
Price/DCF (Projected) 1.73
HITK's Price/DCF (Projected) is ranked higher than
87% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. HITK: 1.73 )
HITK' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 3.96
Current: 1.73

0.6
3.96
Price/Median PS Value 1.25
HITK's Price/Median PS Value is ranked higher than
69% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. HITK: 1.25 )
HITK' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 2.58
Current: 1.25

0.31
2.58
Price/Graham Number 2.72
HITK's Price/Graham Number is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.75 vs. HITK: 2.72 )
HITK' s 10-Year Price/Graham Number Range
Min: 0.64   Max: 3.65
Current: 2.72

0.64
3.65
Earnings Yield (Greenblatt) 7.10
HITK's Earnings Yield (Greenblatt) is ranked higher than
83% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. HITK: 7.10 )
HITK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 29.4
Current: 7.1

0.2
29.4
Forward Rate of Return (Yacktman) -3.15
HITK's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. HITK: -3.15 )
HITK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.8   Max: 52.5
Current: -3.15

-2.8
52.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HT6.Germany
Hi-Tech Pharmacal Co., Inc. is incorporated in Delaware in 1982. The company is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. It develops, manufacture and market products in three categories namely generics, prescription brands and over the counter ('OTC') brands. It produce a wide range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. The generic product category includes a small amount of contract manufacturing sales for both the prescription and OTC markets. Its Health Care Products Division ('HCP') markets a line of OTC branded products for people with diabetes, including Diabetic Tussin , DiabetiDerm, Multi-betic, Mag-Ox, Choice DM and DiabetiSweet. The division also sells the Zostrix brand of capsaicin products for pain management of conditions including arthritis and foot pain. In addition, HCP markets Nasal Ease homeopathic allergy reliever and the recently acquired Sinus Buster brand homeopathic sinus congestion reliever. Its ECR Pharmaceuticals ('ECR Pharmaceuticals' or 'ECR') subsidiary is engaged in the marketing and distribution of branded prescription pharmaceuticals. ECR's products treat various disease states, including tension headache, pain, cough/cold and allergies, contact dermatitis, wound care, sleep disorders and swimmer's ear. Its customers include chain drug stores, drug wholesalers, and managed care purchasing organizations, certain Federal government agencies, generic distributors, mass merchandisers, and mail-order pharmacies. Some of its key customers include McKesson Corporation, Walgreens, Cardinal Health, Inc., AmeriSourceBergen Corporation, CVS and Medco. The company has 55 prescription products approved for marketing by the U.S. Food and Drug Administration ('FDA') and one product with tentative approval. In addition, it has 18 products submitted to the FDA pending approval, including one product, mesalamine, filed by another company in which the Company has approximately a 45% financial interest and approximately 25 products in various stages of development. Its products and facilities are subject to regulation by a number of Federal and state governmental agencies.
» More Articles for HITK

Headlines

Articles On GuruFocus.com
Six Royce Reductions in Third Quarter Oct 09 2013 
Chuck Royce Reductions – Lessons on Hold’em or Fold’em Sep 10 2013 
Good ROE, ROA Jan 21 2013 
The Royce Funds Makes Moves on Some Tech Stocks Dec 07 2012 
comment on HITK Jul 13 2012 
comment on HITK Jul 13 2012 
There’s No Magic Bullet Feb 14 2012 
Value Idea Contest, A Year Later Jan 20 2012 
HITK: A Promising Generic Drug Value Play Jul 19 2011 
March Value Idea Contest Results Announcement; April Contest Is Now Accepting Submissions Apr 12 2012 

More From Other Websites
Akorn plans $440M acquisition of VersaPharm May 09 2014
HI TECH PHARMACAL CO INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Apr 17 2014
Akorn Completes Acquisition of Hi-Tech Pharmacal Apr 17 2014
Repligen Corporation Set to Join the S&P SmallCap 600 Apr 15 2014
Akorn gets FTC clearance for Hi-Tech Pharmacal deal Apr 14 2014
Akorn Receives FTC Clearance for Hi-Tech Pharmacal Acquisition Apr 14 2014
HI TECH PHARMACAL CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Mar 21 2014
HI TECH PHARMACAL CO INC Financials Mar 15 2014
HI TECH PHARMACAL CO INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 12 2014
HI TECH PHARMACAL CO INC Files SEC form 10-Q, Quarterly Report Mar 11 2014
Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014 Mar 11 2014
Akorn Guidance Worries Street As Strategy Hits Delays Mar 03 2014
Akorn Q4 Meets But Guidance Disappoints, Stock Down Mar 03 2014
IntelGenx Technologies: A Small Cap Company With The Potential For Significant Gains Jan 26 2014
Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day) Jan 23 2014
Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day) Jan 23 2014
Allergan Wins Order Blocking Copies of Lumigan Until 2027 Jan 14 2014
Hi-Tech Pharmacal in $25M Medicaid settlement Dec 26 2013
HI TECH PHARMACAL CO INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 26 2013
Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation Dec 26 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK